Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.IJBIOMAC.2019.12.193 | ||||
| Año | 2020 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
A novel composite hydrogel was prepared as a dual drug delivery carrier. Poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) microparticles were prepared to encapsulate simultaneously ketoprofen and mupirocin, as hydrophobic drug models. These microparticles were embedded in a physically crosslinked hydrogel of kappa-carrageenan/locust bean gum. This composite hydrogel showed for both drugs a slower release than the obtained rele(a)se from microparticles and hydrogel separately. The release of both drugs was observed during a period of 7 days at 37 degrees C. Different kinetic models were analyzed and the results indicated the best fitting to a Higuchi model suggesting that the release was mostly controlled by diffusion. Also, the drug loaded microparticles were spherical with average mean particle size of 1.0 mu m, mesoporous, and distributed homogeneously in the hydrogel. The composite hydrogel showed a thermosensitive swelling behavior reaching 183% of swelling ratio at 37 degrees C. The composite hydrogel showed the elastic component to be higher than the viscous component, indicating characteristics of a strong hydrogel. The biocompatibility was evaluated with in vitro cytotoxicity assays and the results indicated that this composite hydrogel could be considered as a potential biomaterial for dual drug delivery, mainly for wound healing applications. (C) 2019 Elsevier B.V. All rights reserved.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Pettinelli, Natalia | Mujer |
Univ A Coruna - España
Universidade da Coruña - España |
| 2 | RODRIGUEZ-LLAMAZARES, SADDYS MARIA | - |
Centro de Investigacion de Polimeros Avanzados - Chile
|
| 3 | Farrag, Yousof | - |
Univ A Coruna - España
Universidade da Coruña - España |
| 4 | Bouza, R. | Mujer |
Univ A Coruna - España
Universidade da Coruña - España |
| 5 | Barral, Luis | Hombre |
Univ A Coruna - España
Universidade da Coruña - España |
| 6 | Feijoo-Bandin, Sandra | Mujer |
Univ Clin Hosp - España
Ctr Biomed Res Network Cardiovasc Dis CIBERCV - España Complejo Hospitalario Universitario de Santiago - España Center for Biomedical Research Network in Cardiovascular Diseases (CIBERCV) - España Hospital Clínico Universitario de Santiago - España Centro de Investigación en Red en Enfermedades Cardiovasculares - España |
| 7 | Lago, Francisca | Mujer |
Univ Clin Hosp - España
Ctr Biomed Res Network Cardiovasc Dis CIBERCV - España Complejo Hospitalario Universitario de Santiago - España Center for Biomedical Research Network in Cardiovascular Diseases (CIBERCV) - España Hospital Clínico Universitario de Santiago - España Centro de Investigación en Red en Enfermedades Cardiovasculares - España |
| Fuente |
|---|
| Fondef |
| Comisión Nacional de Investigación Científica y Tecnológica |
| European Regional Development Fund |
| Fondo de Fomento al Desarrollo Científico y Tecnológico |
| Xunta de Galicia |
| Federación Española de Enfermedades Raras |
| Consejo Nacional de Innovacion, Ciencia y Tecnologia |
| University of Santiago de Compostela |
| CONICYT PIA/APOYO CCTE |
| CIPA, CONICYT Regional, GORE BIO BIO |
| BIO BIO |
| Xunta de Galicia Government/FEDER: Program of Consolidation and Structuring Competitive Research Units |
| Agradecimiento |
|---|
| This work was supported by the Xunta de Galicia Government/FEDER: Program of Consolidation and Structuring Competitive Research Units [GRC 2014/036]. This work was supported by FONDEF ID16I10425; CIPA, CONICYT Regional, GORE BIO BIO, R17A10003; CONICYT PIA/APOYO CCTE AFB170007. The authors also thank to Nanobiofar research group in the Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela (USC), where the Zetasizer Nano ZS90 was used to characterize the MPs. |
| This work was supported by the Xunta de Galicia Government/FEDER: Program of Consolidation and Structuring Competitive Research Units [GRC 2014/036]. This work was supported by FONDEF ID16I10425; CIPA, CONICYT Regional, GORE BIO BIO, R17A10003; CONICYT PIA/APOYO CCTE AFB170007. The authors also thank to Nanobiofar research group in the Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela (USC), where the Zetasizer Nano ZS90 was used to characterize the MPs. |